News

Halozyme Therapeutics (HALO) heads into a busy investor calendar, with management scheduled to speak at three major healthcare and investment conferences in early and mid September 2026, putting the stock back under the spotlight. Despite a slight pullback with a 1-day share price return of 1.57% and a 7-day share price return of 1.90%, Halozyme Therapeutics has built strong momentum, with a 30-day share price return of 7.69% and a 90-day gain of 54.95% helping lift the year-to-date share...

Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.

Four PEG value stocks Halozyme, Avnet, BILL and Venture Global combine discounted valuations with strong expected growth rates.

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.

Halozyme (NASDAQ:HALO) will participate in three healthcare investor conferences during September, giving management multiple opportunities to discuss its commercially validated ENHANZE platform and expanding portfolio of drug delivery technologies. Key Investor TakeawaysHalozyme (NASDAQ:HALO) management will participate in investor events hosted by Wells Fargo, Morgan Stanley and H.

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.

Here is how BioCryst Pharmaceuticals (BCRX) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.

Listen to the angel on your shoulder and avoid the deadly sin of greed. Here's why we sold HALO stock before its fall from grace.

Does Halozyme Therapeutics (HALO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Halozyme Therapeutics stock has delivered a strong share price run over the past few years, yet current valuation checks suggest the stock leans expensive on traditional market multiples and does not screen as a clear bargain overall. Over the past 3 years, Halozyme Therapeutics has returned about 151%, which puts extra focus on whether the current share price already bakes in much of the good news. The recent appointment of Dannielle Appelhans to the Board may support confidence in...

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 24.9% over the past six months, topping the S&P 500 by 13.3 percentage points.

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position HALO, RGEN, IOVA, ARQT and PGEN in this volatile sector.

NeoGenomics (NEO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from scaled industry giants and can be disrupted by new innovative players vying for a slice of the pie.

Halozyme Therapeutics delivered a notably positive second quarter, as evidenced by the strong market reaction and management’s attribution of outperformance to surging royalty revenue and a wave of new collaboration agreements. CEO Helen Torley highlighted that the ENHANZE platform, now underpinning revenue from six different drugs, enabled a record 50% year-over-year royalty growth. The quarter also benefited from sizable milestone payments tied to newly signed licensing deals, with Torley emph

On July 20, Halozyme Therapeutics, Inc. (NASDAQ:HALO) and Incyte Corporation (NASDAQ:INCY) announced a global collaboration and licensing deal to develop a subcutaneous formulation of Incyte’s INCA033989. The first-in-class monoclonal antibody targets mutant calreticulin (mutCALR)-expressing myeloproliferative neoplasms. By utilizing Halozyme’s proprietary ENHANZE drug delivery technology, INCY aims to create a more convenient dosing regimen for patients. […]

Revenue jumped 48% to $481 million on record royalty growth.

Halozyme Therapeutics (HALO) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here is how Halozyme Therapeutics (HALO) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.

Shares of biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) jumped 18.1% in the afternoon session after the company reported strong second-quarter earnings that surpassed analyst expectations and raised its full-year financial guidance.

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.

Halozyme's ENHANZE platform drives a 48% revenue surge, with new partnerships and Hypercon progress fueling a second growth engine.

Natera and Halozyme Therapeutics saw gains above 15%, led by bullish Wall Street commentary after better-than-expected second-quarter results.

Moby summary of Halozyme Therapeutics, Inc.'s Q2 2026 earnings call

Halozyme Therapeutics (NASDAQ:HALO) reported record second-quarter revenue and raised its full-year outlook, citing growth in royalty income from its ENHANZE drug-delivery platform, contributions from newer product launches and revenue from newly signed collaboration agreements. Total revenue rose

Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +25.28% and +17.44%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.

Halozyme Therapeutics is at a new high on Friday with earnings due on Aug. 6. Philip Morris International and KeyCorp are also at highs.